Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
289 studies found for:    sirolimus cancer | Open Studies
Show Display Options
Rank Status Study
21 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
22 Recruiting Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer
Intervention: Drug: everolimus and letrozole
23 Recruiting Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Letrozole;   Drug: Everolimus;   Drug: TRC105
24 Recruiting Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor-negative;   Stage IV Breast Cancer;   Triple-negative Breast Carcinoma
Interventions: Drug: everolimus;   Drug: eribulin mesylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
25 Recruiting Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Condition: Refractory Hurthle Cell Thyroid Cancer
Interventions: Drug: sorafenib;   Drug: everolimus
26 Recruiting VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Conditions: Adenocarcinoma;   Pancreatic Neoplasms
Interventions: Drug: X-82;   Drug: Everolimus;   Procedure: Blood draws for pharmacokinetic testing
27 Recruiting Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Condition: Breast Cancer
Interventions: Drug: Ribociclib;   Drug: Everolimus;   Drug: Exemestane
28 Not yet recruiting Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus;   Drug: Goserelin;   Drug: Letrozole
29 Recruiting DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Conditions: HER2-negative Und Hormone-receptor Positive Metastatic Breast Cancer;   HER2-negative Circulating Tumor Cells;   Postmenopausal Female Patients
Interventions: Drug: Everolimus;   Drug: Eribulin
30 Recruiting A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Conditions: Solid Tumors;   Lung Cancer
Interventions: Drug: BKM120;   Drug: Everolimus
31 Recruiting Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
Condition: Cancer
Interventions: Drug: Sirolimus;   Drug: Celecoxib;   Drug: Etoposide;   Drug: Cyclophosphamide
32 Recruiting Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
Conditions: Primary Non-metastatic Breast Cancer;   Who Remain Disease-free
Interventions: Drug: Everolimus;   Drug: Placebo
33 Recruiting A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Condition: Desmoid Tumor
Intervention: Drug: Sirolimus
34 Recruiting Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Carcinoma;   Lung Adenocarcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Auranofin;   Drug: Sirolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
35 Recruiting A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
Condition: Relapsed / Recurrent Germ Cell Tumors
Interventions: Drug: Erlotinib;   Drug: Sirolimus
36 Recruiting Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Conditions: Advanced Malignant Neoplasm;   Cervical Squamous Cell Carcinoma;   Endometrial Carcinoma;   Malignant Uterine Neoplasm;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Head and Neck Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Solid Neoplasm;   Stage III Bladder Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Bladder Cancer;   Stage IVA Cervical Cancer;   Stage IVB Bladder Cancer;   Stage IVB Cervical Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nanoparticle Albumin-Bound Rapamycin;   Other: Quality-of-Life Assessment
37 Recruiting Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Drug: Exemestane;   Drug: Everolimus
38 Recruiting Everolimus for Cancer With TSC1 or TSC2 Mutation
Conditions: TSC1;   TSC2;   Tuberous Sclerosis Complex;   MTOR
Intervention: Drug: Everolimus
39 Recruiting LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
Condition: Esophageal Cancer
Interventions: Drug: Everolimus;   Drug: LDE 225
40 Recruiting PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
Condition: Metastatic Renal Cancer
Intervention: Drug: Prednisone + Everolimus

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years